Repligen (RGEN) Tops Q4 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to Repligen (RGEN) Tops Q4 EPS by 16c

Repligen Reports Fourth Quarter and Full Year 2021 Financial Results

February 17, 2022 7:30 AM EST

Record revenue of $186.5 million for the quarter, and year-over-year growth of 72%

Record revenue of $670.5 million for the year, and year-over-year growth of 83%

Organic revenue growth of 69% for the fourth quarter and 71% for the year 2021

Completes acquisition of single-use fluid management component manufacturer BioFlex Solutions

WALTHAM, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2021. Provided in this press release are... More